Effect of carperitide on plasma adiponectin levels in acute decompensated heart failure patients with diabetes mellitus.
BACKGROUND
It is reported that adiponectin has a cardioprotective effect and is decreased in type 2 diabetes mellitus (DM).


RESULTS
The effect of carperitide (atrial natriuretic peptide: ANP) on plasma adiponectin levels was evaluated in acute decompensated heart failure (ADHF) patients with and without DM. In 47 patients (DM: n=11) who were admitted with ADHF, blood samples were collected before and 7 days after administration of carperitide. The plasma levels of ANP, brain natriuretic peptide (BNP), aldosterone and adiponectin were measured. Plasma adiponectin levels were significantly increased (17.6 +/-1.5 to 19.6 +/-1.8 microg/ml, P=0.0003) concomitant with the increase in ANP and decrease in BNP 7 days after carperitide infusion. Although adiponectin levels before treatment were slightly lower in ADHF patients with DM, the % increase in adiponectin levels was significantly greater in ADHF patients with DM than in those without DM (26.7 vs 6.6%, P=0.007). In the stepwise multivariate analyses, a higher plasma aldosterone levels before treatment (P=0.04) and DM (P=0.01) were significant independent predictors of a greater % increase in adiponectin levels after treatment with carperitide.


CONCLUSIONS
Carperitide infusion increases the plasma adiponectin level, especially in ADHF patients with DM.
Yamaji
Masayuki
M
Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Otsu, Japan.
Tsutamoto
Takayoshi
T
Tanaka
Toshinari
T
Kawahara
Chiho
C
Nishiyama
Keizo
K
Yamamoto
Takashi
T
Fujii
Masanori
M
Horie
Minoru
M
D000208:Acute Disease; D052242:Adiponectin / Q000097:blood; D000368:Aged; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D048909:Diabetes Complications / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007263:Infusions, Parenteral; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010865:Pilot Projects; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D002317:Cardiovascular Agents; C472955:NPPA protein, human; D020097:Natriuretic Peptide, Brain; D000450:Aldosterone; D009320:Atrial Natriuretic Factor